Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06679101




Registration number
NCT06679101
Ethics application status
Date submitted
6/11/2024
Date registered
7/11/2024
Date last updated
15/05/2025

Titles & IDs
Public title
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Scientific title
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Secondary ID [1] 0 0
2024-516030-35
Secondary ID [2] 0 0
214828
Universal Trial Number (UTN)
Trial acronym
DREAMM-10
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Newly Diagnosed Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Belantamab mafodotin
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Daratumumab

Experimental: Arm A: Belantamab Mafodotin + Lenalidomide + Dexamethasone - Belantamab mafodotin, lenalidomide, and dexamethasone will be administered.

Treatment will continue in both arms until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.

Active comparator: Arm B: Daratumumab + Lenalidomide + Dexamethasone - Daratumumab, lenalidomide, and dexamethasone will be administered.

Treatment will continue in both arms until PD, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.


Treatment: Drugs: Belantamab mafodotin
Belantamab mafodotin will be administered.

Treatment: Drugs: Lenalidomide
Lenalidomide will be administered.

Treatment: Drugs: Dexamethasone
Dexamethasone will be administered.

Treatment: Drugs: Daratumumab
Daratumumab will be administered.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
PFS
Timepoint [1] 0 0
Up to approximately 7 years
Primary outcome [2] 0 0
Number of Participants Achieving MRD Negative Status
Timepoint [2] 0 0
Up to approximately 7 years
Secondary outcome [1] 0 0
PFS2
Timepoint [1] 0 0
Up to approximately 7 years
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to approximately 7 years
Secondary outcome [3] 0 0
Number of Participants Achieving CR or Better (CR+)
Timepoint [3] 0 0
Up to approximately 7 years
Secondary outcome [4] 0 0
Number of Participants Achieving Very Good Partial Response (VGPR) or Better
Timepoint [4] 0 0
Up to approximately 7 years
Secondary outcome [5] 0 0
Number of Participants Achieving Sustained MRD Negative Status
Timepoint [5] 0 0
Up to approximately 7 years
Secondary outcome [6] 0 0
Duration of Response (DoR)
Timepoint [6] 0 0
Up to approximately 7 years
Secondary outcome [7] 0 0
Time to Second Next Line Therapy (TTST)
Timepoint [7] 0 0
Up to approximately 7 years
Secondary outcome [8] 0 0
Number of Participants With Adverse Events (AEs)
Timepoint [8] 0 0
Up to approximately 7 years
Secondary outcome [9] 0 0
Number of Participants With Ocular Findings on Ophthalmic Exam
Timepoint [9] 0 0
Up to approximately 7 years
Secondary outcome [10] 0 0
Maximum Post-baseline Patient-Reported Outcomes Version of the Common Term Criteria for Adverse Events (PRO-CTCAE) Score
Timepoint [10] 0 0
Up to approximately 7 years
Secondary outcome [11] 0 0
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30
Timepoint [11] 0 0
Up to approximately 7 years
Secondary outcome [12] 0 0
Change From Baseline in EORTC QLQ-MY20
Timepoint [12] 0 0
Up to approximately 7 years
Secondary outcome [13] 0 0
Plasma Concentrations of Belantamab Mafodotin
Timepoint [13] 0 0
Up to approximately 7 years
Secondary outcome [14] 0 0
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Timepoint [14] 0 0
Up to approximately 7 years
Secondary outcome [15] 0 0
Titers of ADAs Against Belantamab Mafodotin
Timepoint [15] 0 0
Up to approximately 7 years

Eligibility
Key inclusion criteria
1. Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.
2. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the protocol.
3. NDMM with a requirement for treatment as documented per IMWG criteria.
4. Must have at least 1 aspect of measurable disease, as assessed by the central laboratory, defined as 1 of the following:

1. Urine M-protein excretion =200 mg/24 hours (=0.2 g/24 hours) And/or
2. Serum M-protein concentration =0.5 g/dL (=5.0 g/L) And/or
3. Serum free light-chain (FLC) assay: involved FLC level =10 mg/dL (=100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65).
5. Newly diagnosed and not considered candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to any of the following:

1. =70 years of age, OR
2. Age 18 to 69 years with presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT, (or for whom national guidelines do not permit transplant due to a cut-off age below 70 years), OR
3. Who refuse high-dose chemotherapy with ASCT as an initial treatment.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
7. Adequate organ system function as defined by the laboratory assessments.
8. Male participants:

* Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* Male participants are eligible to participate if they agree to the following during the Treatment Period and for at least 6 months after the last dose of study intervention to allow for clearance of any altered sperm:
* Refrain from donating fresh unwashed semen

PLUS either:
* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.

OR
* Must agree to use contraception/barrier as detailed below
* Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant. Male participants should also use a condom when having sexual intercourse with pregnant females.
9. Female participants

* Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
* Is not a WOCBP OR
* Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency during the Treatment Period and for 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
* A WOCBP must have 2 negative highly sensitive serum pregnancy tests before starting treatment, the first may be performed within 14 days from C1D1, the second within 24 hours before the first dose of study intervention.
* Should pregnancy occur in a female on treatment or the female partner of a male on treatment, treatment must be stopped, and it is advised to seek advice from a physician specialized or experienced in teratology.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Diagnosis of systemic amyloid light chain amyloidosis, Waldenstrom's disease, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes) or Primary Plasma Cell Leukemia (defined as circulating plasma cells >5%).
2. Prior systemic therapy for multiple myeloma, or smoldering multiple myeloma.
3. Signs of meningeal or central nervous system involvement with multiple myeloma.
4. Major surgery within 2 weeks prior to the first dose of study drugs or has not recovered fully from surgery. Kyphoplasty is not considered major surgery.
5. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent, or compliance with study procedures.
6. Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease as per the investigator's assessment).
7. Participants with previous or concurrent malignancies other than multiple myeloma are excluded. Exceptions are any other malignancy that has been considered medically stable for at least 2 years, after discussion with the GSK Medical Monitor. The participant must not be receiving active therapy, other than hormonal therapy for this disease.
8. Evidence of cardiovascular risk including any of the following:

1. Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular block.
2. Recent history (within 3 months of screening) of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty or stenting, or bypass grafting.
3. Class III or IV heart failure as defined by the New York Heart Association functional classification system.
9. Known human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:

1. Established antiretroviral therapy for at least 4 weeks and HIV viral load <400 copies/mL within Screening Period.
2. CD4+ T-cell (CD4+) counts =350 cells/µL.
3. No history of acquired immune deficiency syndrome-defining opportunistic infections within the last 12 months.
10. Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention unless the participant can meet the following criteria:

1. RNA test negative.
2. Successful antiviral treatment (usually 8 weeks duration) is required, followed by a negative hepatitis C viral load RNA test after a washout period of at least 4 weeks.
11. Participants with hepatitis B will be excluded unless the defined criteria can be met.
12. Current corneal epithelial disease except for mild punctate keratopathy.
13. Intolerance or contraindications to antiviral prophylaxis.
14. Unable to tolerate antithrombotic prophylaxis.
15. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study intervention.
16. Plasmapheresis within 7 days prior to the first dose of study intervention.
17. Participants must not have received a live or live-attenuated vaccine within 30 days prior to first dose of belantamab mafodotin.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/12/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
6/04/2032
Actual
Sample size
Target
520
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
GSK Investigational Site - Gosford NSW
Recruitment hospital [2] 0 0
GSK Investigational Site - Fitzroy
Recruitment postcode(s) [1] 0 0
2250 - Gosford NSW
Recruitment postcode(s) [2] 0 0
- Fitzroy
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Capital Federal
Country [2] 0 0
Argentina
State/province [2] 0 0
Ciudad Autonoma de Buenos Aire
Country [3] 0 0
Argentina
State/province [3] 0 0
Rosario
Country [4] 0 0
Argentina
State/province [4] 0 0
Viedma
Country [5] 0 0
China
State/province [5] 0 0
Beijing
Country [6] 0 0
China
State/province [6] 0 0
Shanghia
Country [7] 0 0
China
State/province [7] 0 0
Tianjin
Country [8] 0 0
Japan
State/province [8] 0 0
Aichi
Country [9] 0 0
Japan
State/province [9] 0 0
Ehime
Country [10] 0 0
Japan
State/province [10] 0 0
Fukushima
Country [11] 0 0
Japan
State/province [11] 0 0
Gunma
Country [12] 0 0
Japan
State/province [12] 0 0
Hyogo
Country [13] 0 0
Japan
State/province [13] 0 0
Ibaraki
Country [14] 0 0
Japan
State/province [14] 0 0
Iwate
Country [15] 0 0
Japan
State/province [15] 0 0
Miyagi
Country [16] 0 0
Japan
State/province [16] 0 0
Nara
Country [17] 0 0
Japan
State/province [17] 0 0
Sapporo
Country [18] 0 0
Japan
State/province [18] 0 0
Suita
Country [19] 0 0
Japan
State/province [19] 0 0
Tokyo
Country [20] 0 0
Japan
State/province [20] 0 0
Yamagata
Country [21] 0 0
Korea, Republic of
State/province [21] 0 0
Hwasun
Country [22] 0 0
Korea, Republic of
State/province [22] 0 0
Jeonju
Country [23] 0 0
Korea, Republic of
State/province [23] 0 0
Seoul
Country [24] 0 0
Korea, Republic of
State/province [24] 0 0
Ulsan
Country [25] 0 0
Poland
State/province [25] 0 0
Lublin
Country [26] 0 0
Spain
State/province [26] 0 0
Madrid
Country [27] 0 0
Spain
State/province [27] 0 0
Murcia
Country [28] 0 0
Spain
State/province [28] 0 0
Valladolid
Country [29] 0 0
Taiwan
State/province [29] 0 0
Kaohsiung

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
US GSK Clinical Trials Call Center
Address 0 0
Country 0 0
Phone 0 0
877-379-3718
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06679101